Evidence map›Paper›PMID 36405728›Full record

ArticleFrontiers in immunology2022

Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.

Yan Qin, Jie Yang, Cao Liang, Jun Liu, Zhixing Deng, Binli Yan, Ying Fu, Yinghua Luo, Xiaozhen Li, Xiaoying Wei and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Integrating computational engines to identifyFrontiers in immunology · 2026
    Article
  14. Migrasomes: A Novel Target for Cancer Treatment.Current cancer drug targets · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yan QinDepartment of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region and Research center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
Jie YangDepartment of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region and Research center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
Cao LiangDepartment of Surgical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Jun LiuDepartment of Surgical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Zhixing DengDepartment of Surgical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Binli YanDepartment of Surgical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Ying FuDepartment of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region and Research center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
Yinghua LuoDepartment of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region and Research center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
Xiaozhen LiDepartment of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region and Research center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
Xiaoying WeiDepartment of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region and Research center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
Wei LiDepartment of Health Management, The People's Hospital of Guangxi Zhuang Autonomous Region and Research center of Health Management, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
The People's Hospital of Guangxi Zhuang Autonomous Region · CNGuangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The migrasome is a newly discovered organelle that resembles extracellular vesicles in structure. However, the function of the migrasome in tumors, particularly in relation to tumor immunity and tumor microenvironment, is unclear. Methods: Gene expression data, copy number variation raw data, and methylation data of 33 cancer types were downloaded from The Cancer Genome Atlas database. Immunohistochemistry (IHC) based on 114 case of colorectal cancer was used to validate the expression of the migrasome hub-gene. We analyzed the expression, prognosis, genetic variation, and drug sensitivity profiles of migrasome-related genes (MRGs) in pan-cancer datasets. A migrasome score was constructed based on gene set enrichment analysis, and the correlation of migrasomes with the tumor microenvironment was assessed. The CancerSEA was used to perform a single-cell level functional analysis of the migrasome. Additionally, we also analyzed the correlation between migrasomes and tumor mutational burden (TMB), microsatellite instability (MSI), and tumor immune dysfunction and exclusion scores. Single-cell transcriptome sequencing (scRNA-seq) data was used to assess the activation state of migrasomes in the tumor microenvironment. Results: PIGK expression was significantly up-regulated in 22 of 33 tumors, and high expression of migrasome was estimated to have contributed to poor prognosis. Missense mutations are the most common type of mutation in MRGs. We identified piperlongumine as a potential drug targeting migrasomes. The migrasome score was significantly and positively correlated with the tumor immunity score and the stroma score. In most tumors, the abundance of macrophages in the tumor microenvironment was significantly and positively correlated with the migrasome score. Additionally, the migrasome scores were significantly correlated with the immune checkpoint genes in pan-cancer as well as immune checkpoint therapy-related markers including TMB and MSI. According to scRNA-seq analysis, migrasome differed significantly among cells of the tumor microenvironment. IHC confirmed low expression of ITGA5 and PIGK in colorectal cancer. Discussion: We performed the first pan-cancer analysis of migrasomes and discovered that they play an important role in tumor development and immune escape. Our study provides new insights into the role of migrasomes in tumor prognosis and immunotherapy.

Indexed as

Colorectal NeoplasmsDNA Copy Number VariationsBiomarkers, TumorHumansImmunotherapyMicrosatellite InstabilityOrganellesTumor MicroenvironmentBiomarkers, Tumorimmune checkpoint inhibitorsmigrasomepan-cancerscRNA-seqtumor immunitytumor microenvironment

Identifiers

PMID36405728
PMCPMC9669594
OpenAlexW4308416208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.